Leadership & Pay ·
Longeveron Inc. entered into a revised letter agreement with CEO Stephen Willard on July 8, 2026, amending and…
LGVNLongeveron Inc.
Longeveron Inc. entered into a revised letter agreement with CEO Stephen Willard on July 8, 2026, amending and restating the original agreement from February 11, 2026. The revised agreement provides for a $500,000 annual base salary without deferral, an annual cash bonus target of 45% of base salary, and accelerated quarterly vesting of initial equity awards (200,000 RSUs and 200,000 stock options) over a three-year period instead of four. Longeveron Inc. is a biotechnology company focused on developing cell therapies for regenerative medicine.